Bayer: From risks and side effects

In the U.S., what could be brewing for Bayer. For thousands of affected women want to complain against the pharmaceutical giant for alleged negative effects of birth control pills for the Group. That could be expensive.

The Leverkusen-based company is said to have the approval of its birth control pill Yasmin in 2001, the U.S. authorities do not adequately informed about possible risks and side effects. The said David Kessler, former head of the U.S. Food and Drug Administration in court dispute over the contraceptive Yasmin and Yaz. Thus, Bayer confronted with serious accusations.

It's mostly about alleged risks of thrombosis from Yasmin, which was already approved in 2001 and is also true for drug tests, had appeared in which dangerous blood clots in women. These allegations are now produced from files that were open on Monday in a court in the U.S. state of Illinois.
Bayer

47.17 +0.13 +0.28%
Wave of action
Thousands of women in the U.S. now sue for damages. Those claims is not to be trifled known. By early October, the number of applicants has already increased to 10,400. Although the company is insured against product liability risks, but it is feared that this will not suffice for a conviction. Bayer declined to comment on the matter and referred to the ongoing process: "This is is a matter which is the subject of ongoing legal proceedings and will be dealt with accordingly in court," said a spokesman. Bayer plans but decided to defend against the allegations.

Particularly important will be how the experts committee to the FDA expresses that deals with the matter this week. His vote is of great importance for the future of Bayer pills in the U.S..
One of the most important business
The threat to Bayer becomes clearer if one bears in mind that the birth control pill Yasmin product family with an annual turnover of 1.1 billion euros, the second largest group in the pharmaceutical sales business are. A further complication is that sales are declining, because the competition is located in the neck Bayer difficult. Many vendors offer generic copycat products and provide sales declines. Within a year there were at least 13.1 percent.

Bayer stock hardly responds
Investors measure the threat of litigation in the U.S. today, however, no direct meaning. Bayer shares fall in line with a market yielding 0.9 percent to 47.20 euros